Article Details
Retrieved on: 2021-12-20 17:25:56
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Can-Fite BioPharma (CANF) stock is rocketing higher on Monday thanks to new data from a Phase II clinical trial for liver cancer.
Article found on: investorplace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here